Safety Center

The Safety Center is a single hub. It gathers the safety considerations that are relevant across many compound pages so you do not have to reconstruct them each time you open a new one. Individual compound pages describe what the literature reports about that specific molecule; this hub describes the shared context, risk categories, and decision framing that surround every one of them.

Nothing here is a replacement for a clinician who knows your history. Use the Safety Center as an orientation, not as personalised guidance.

Every compound page on Healthy Mango describes a lyophilized "research-use-only" ("RUO") vial. The RUO label is a legal and manufacturing designation. It means the material is sold for laboratory investigation, has not been evaluated by a regulator for a human indication, and has not necessarily been manufactured to pharmaceutical Good Manufacturing Practice standards.

RUO material is not equivalent to an approved medicine even when the underlying molecule is one. An FDA-approved product of the same molecule has been through a manufacturing chain, batch testing, and labelling controls that a research vial has not. Whether it is lawful for a reader in a given jurisdiction to acquire, possess, prepare, or use an RUO vial is a legal question this site does not answer.

An educational website cannot evaluate your medical history, current medications, allergies, laboratory values, or the specific compound in front of you. It can only summarise what published sources have reported about the class of molecule. Two readers with the same weight and the same intended amount can respond very differently to the same compound, and neither response is predictable from reading a web page.

When a specific claim on the site matters for a decision you are considering, verify it independently against the cited source (a peer-reviewed paper, a regulatory label, or the practitioner reference identified on the page). If you cannot find or read the underlying source, treat the claim on the website as informational only, and consult a clinician for anything that touches your own health.

Each compound is tagged with an evidence level (A through D) that summarises the quality and quantity of the underlying human evidence. Level A means multiple well-designed randomised placebo-controlled trials with regulatory approval; Level D means preclinical, in-vitro, or animal-model evidence with little or no human data. Level B and Level C fall between the two.

Evidence level is not a safety rating and not an efficacy prediction for any individual reader. A high-evidence compound may still be inappropriate for a particular person; a low-evidence compound is not necessarily dangerous, only under-studied. Uncertainty is not a synonym for risk, but it is a reason to be conservative.

The "Research Protocols" accordion on a compound page distinguishes between values that appear in the peer-reviewed literature and values that appear in the current practitioner reference used across the site. Peer-reviewed studies have gone through methodological and statistical review; a practitioner reference summarises real-world practice among clinicians and researchers, and is not itself a controlled trial.

Both categories are descriptive, not prescriptive. A dose that appeared in a study or a practitioner reference is not, by virtue of appearing there, safe or appropriate for any particular reader. When the two categories disagree, we present both and label the source; the reader is responsible for their own judgment about which, if any, is relevant to their situation.

Some molecules on the site (for example semaglutide, tirzepatide, bremelanotide) also exist as FDA-approved commercial products under brand names such as Ozempic, Wegovy, Mounjaro, Zepbound, or Vyleesi. Those approved products are referenced on the corresponding compound page as scientific and regulatory context only. They are not the presentation the compound page describes.

The two supply chains are legally, chemically, and pharmacologically distinct. An FDA-approved product carries a specific concentration, a device (a pen or vial), a batch history, and a label; an RUO vial carries none of those guarantees. The existence of an approved product does not validate the identity, purity, potency, or sterility of an RUO vial that shares the same generic name.

A research vial can differ from its label in five distinct ways. It may not be the peptide it claims to be (identity). It may contain impurities such as truncated sequences, oxidised species, or process residues (purity). It may contain a different mass than the label states (potency). It may harbour viable microorganisms introduced during synthesis or fill (sterility). It may contain bacterial cell-wall breakdown products that can cause severe reactions even in the absence of live organisms (endotoxin).

These risks are independent. A vial can have correct identity and still be contaminated. A vial can be sterile and still contain the wrong molecule. Each is verified by a different laboratory method, and none of them is verifiable from the outside of an unopened box.

A Certificate of Analysis ("CoA") is a document a manufacturer or third-party lab issues describing test results for a specific production batch. A CoA is useful evidence, but it is not proof of safety by itself.

• The panel of tests may be incomplete. A CoA showing HPLC purity does not necessarily include sterility, endotoxin, moisture, or heavy-metal testing.
• The document may not match the actual vial in your hand. Batch numbers, dates, and lot codes should agree; if they do not, the CoA is not evidence for that vial.
• Purity is not sterility, and sterility is not identity. A high purity number does not imply a low endotoxin number.
• Endotoxin testing is a distinct assay (LAL or an alternative) with its own limits of detection. "No detectable endotoxin" is a statement about the test's threshold, not an absolute absence.
• Batch-specific verification matters. Trust in a manufacturer's earlier batches is not evidence for a later batch.
• Supplier-authored claims should not be treated as independent evidence. Independent third-party testing carries different weight than a document produced by the party selling the vial.
• Packaging and professional branding do not prove quality. Anyone can print a document, a label, or a box.

No testing method that a research supplier can run establishes fitness for human use. "Analytically clean" is not the same as "approved for administration."

Where a supplier publishes CoAs, verify that the CoA batch number matches the label of the vial in your hand and that the date is consistent with when you received it. Where a supplier does not publish a batch-specific CoA on request, that absence is itself information.

Healthy Mango does not certify, endorse, or authenticate any research supplier. Any transactional or trust relationship a reader may have with a vendor is outside the scope of the Services.

Peptides differ in how sensitive they are to heat and to freeze-thaw cycles. Lyophilized (freeze-dried) material is generally more stable than reconstituted solution, but neither is indestructible. Long transit times, unrefrigerated shipping, or accidental freezing after reconstitution can degrade a peptide silently, and degradation is often not visible.

Follow the storage guidance on the compound page for the specific molecule you are dealing with. If a shipment arrives visibly damaged, or after an unexpectedly long time in transit, treat that batch with more suspicion, not less.

A lyophilized vial contains a dry cake or powder of peptide. It is not a solution. Before it can be measured in millilitres, it has to be dissolved ("reconstituted") in a compatible diluent. The mass of peptide inside the vial does not change during reconstitution; only the volume it occupies changes.

The label on the outside of the vial reports the intended peptide mass. That mass is what the calculator on a compound page treats as the numerator. It is trusted only as far as the vial itself is trusted (see "Identity, purity, potency").

"Bacteriostatic water" contains a small amount of benzyl alcohol as a preservative and is intended for reconstitutions that will be accessed more than once. "Sterile water for injection" contains no preservative and is intended for single use. The two are chemically and functionally different fluids.

Choosing the wrong diluent introduces distinct risks. Benzyl alcohol is not appropriate for every context and can, in specific populations, cause harm. Non-preserved sterile water reconstitutions that are accessed more than once lose their sterility rapidly. Compound pages document the convention used in the practitioner reference for each compound; that documentation is descriptive, not a recommendation for any individual reader.

Concentration is defined as peptide mass divided by diluent volume. A 10 mg vial reconstituted in 2 mL of diluent is 5 mg/mL. That is the only arithmetic the Preparation Calculator performs on this side of the equation.

The volume you inject at that concentration to deliver a particular reported research amount is the reported amount divided by the concentration. For example, a 0.25 mg reported amount at 5 mg/mL is 0.05 mL. On a standard insulin syringe with 100 unit markings representing 1 mL, that is 5 units.

The arithmetic is not the same thing as the decision. A calculator can convert a stated amount into a syringe reading; it cannot tell you whether that stated amount is appropriate for you, whether the vial is what the label says, or whether the route and frequency in the underlying source are relevant to your situation.

Aseptic technique is a set of learned laboratory skills for keeping microorganisms out of a sterile fluid. It includes hand hygiene, disinfection of vial stoppers and skin, appropriate use of single-use needles and syringes, avoidance of contact between needle tip and non-sterile surfaces, and a clean working environment.

A written summary on a website is not aseptic-technique training. If a reader is not comfortable with the practicalities of preparing a sterile injection, that is itself information. Contamination introduced during reconstitution or repeated access is not always visible.

Every time a needle enters a vial stopper the vial's sterility barrier is challenged. Bacteriostatic water reduces the growth of common bacteria that might be introduced, but it does not eliminate risk and it does not neutralise endotoxin. The more times a vial is accessed, the more chances there are for microorganisms or particulate to enter.

Follow the specific compound page's storage window for reconstituted material and treat that window as an upper bound, not a target. When in doubt, discard.

Reconstituted solutions should generally be clear and colourless (unless the compound page specifies otherwise). Visible turbidity, particulate, discolouration, or precipitate is a reason to discard the vial. However, absence of visible abnormality is not evidence of sterility, correct identity, correct potency, or an acceptable endotoxin level. Contamination that matters is usually invisible.

Reconstituted peptide solutions are typically stored refrigerated between 2°C and 8°C, protected from light, and away from freezer conditions that would create freeze-thaw cycles. Compound-specific stability windows vary. Do not extrapolate the stability window of one peptide to another; the underlying chemistry and formulation determine the answer.

Used needles, syringes, and lancets are "sharps" and are regulated waste in most jurisdictions. They should be placed in a puncture-resistant, leak-proof container marked for sharps disposal, not in ordinary household rubbish or recycling. Full sharps containers should be surrendered to the disposal route provided in your jurisdiction (a pharmacy, a hospital, a mail-back service, or a municipal collection point).

Uncapped or improperly discarded sharps expose refuse workers, family members, and pets to preventable needle-stick injuries. If a needle-stick injury occurs, wash the site with soap and water and seek medical evaluation; do not assume the exposure is trivial.

The Preparation Calculator on each compound page performs arithmetic only. It computes concentration as vial mass divided by diluent volume, and it converts a reported research amount into an equivalent volume at that concentration.

The calculator does not verify vial identity, purity, potency, sterility, endotoxin content, or storage history; does not evaluate whether the compound is suitable for a reader; does not test bacteriostatic water quality; and does not recommend a dose, route, frequency, or cycle. Its output is only as accurate as the vial label actually is. If the label misrepresents the peptide mass, the calculator's output is wrong by exactly that margin.

The conversion from a milligram or microgram amount to a syringe reading depends on the concentration you actually reconstituted to, on the syringe you are using, and on which markings that syringe uses (units versus millilitres). A single arithmetic mistake in this chain can produce a ten- or hundred-fold error.

Cross-check the calculator's output against the source it is derived from. If the number surprises you, treat that surprise as a reason to stop and re-verify rather than as a reason to proceed.

The pharmacokinetics of a peptide depend heavily on the route by which it is administered. Subcutaneous, intramuscular, intranasal, intravenous, oral, sublingual, and topical routes produce very different absorption profiles, half-lives, and peak concentrations. A dose reported for one route cannot be assumed to be appropriate for another route.

Formulations designed for one route (for example nasal sprays, transdermal patches, or oral capsules) are often not interchangeable with formulations for another route. A vial intended for subcutaneous reconstitution is not automatically usable intranasally, and vice versa. Compound pages describe the presentation the practitioner reference uses; that presentation is not necessarily transferable to a different route.

Peptides and research compounds can interact with prescription and over-the-counter medications, with other peptides, with supplements, and with alcohol. Many of these interactions have not been formally studied and are inferred, rather than known, from the pharmacology of the individual molecules.

"No known interaction" is not the same as "no interaction." Formal drug-interaction studies exist for approved medicines; they generally do not exist for the RUO landscape. Absence of a reported interaction should not be read as evidence of safety.

Human response to any biologic molecule varies substantially between individuals. Age, sex, body composition, genetics, concurrent medications, comorbidities, hydration, sleep, stress, prior exposure, and factors that are not yet well characterised all affect how a molecule is metabolised, tolerated, and experienced.

The compound page tells you what has been reported in populations. It cannot predict what will happen in one reader. When a reader's response deviates from the reported range, that deviation is not necessarily an error in the source; it may be a signal about the reader.

Certain categories of reader face greater uncertainty than the general adult research population that most published data describes. The list below is not exhaustive and is not a set of eligibility rules; it is a set of situations where consulting a qualified clinician before making any decision is more important, not less.

• pregnant or breastfeeding individuals
• minors (under 18)
• older adults, especially over 75
• people with cardiovascular disease
• people with kidney or liver impairment
• people with diabetes
• people using glucose-lowering medication (insulin, sulfonylureas, GLP-1 agonists)
• people with endocrine disorders (thyroid, adrenal, pituitary)
• people with a personal or family history of cancer
• people with severe allergy or anaphylaxis history
• people taking multiple medications (polypharmacy)

Most peptide research explicitly excludes pregnant and breastfeeding participants. The absence of data about a compound in pregnancy is not evidence of safety in pregnancy; it is the reason regulators default to caution. Do not extrapolate data from a general adult research cohort to a pregnancy context.

Healthy Mango's content is intended for adults aged 18 or older. The published data underlying the site is drawn overwhelmingly from adult populations. Extrapolating any of the site's content, or any calculator output, to paediatric use is unsupported and outside the scope of what the site can inform.

Compounds that affect heart rate, blood pressure, fluid balance, vasodilation, coagulation, or lipid handling can pose additional risk for people with pre-existing cardiovascular disease. Personal history of ischaemic heart disease, arrhythmia, hypertension, heart failure, or stroke is a reason to raise concerns with a qualified clinician before considering any research compound, not to rely on a web page.

The kidneys and liver handle the clearance and metabolism of most biologics. Impaired renal or hepatic function can alter half-life, plasma exposure, and metabolite accumulation, sometimes dramatically. Reported dose ranges derived from participants with normal organ function do not necessarily apply where function is reduced.

Peptides in the GLP-1, GIP, glucagon, and related families lower blood glucose. Adding one to an existing glucose-lowering regimen (insulin, sulfonylureas, or another GLP-1 agonist) can produce clinically important hypoglycaemia. Anyone taking a glucose-lowering medication should discuss any new peptide with their clinician before considering it.

Compounds acting on growth hormone, insulin-like growth factor, ACTH, cortisol, thyroid, gonadal hormones, prolactin, or oxytocin can shift a patient with an existing endocrine disorder off a fragile equilibrium. Where the underlying condition is being managed with medication, the interaction with a research peptide is generally not well studied.

Some peptides act on growth-promoting pathways (for example the GH/IGF-1 axis or angiogenic pathways) that are also relevant to cancer biology. Personal or family history of cancer is a reason to discuss any research compound with a qualified clinician; the site does not attempt to weigh oncologic risk for individual readers.

Peptides can trigger allergic reactions ranging from mild local irritation to anaphylaxis. Reaction risk is not predictable from the peptide's mechanism or from the size of prior exposures. A personal history of severe allergy, mast-cell activation, or anaphylaxis is a reason to be materially more cautious. See the emergency warning at the top of this page for signs of anaphylaxis.

The risk of a clinically significant drug–drug interaction grows with the number of medications a person is taking. A reader on five or more chronic medications is in a different category of interaction risk than someone taking none. That is a reason to involve a clinician, and specifically a pharmacist, before adding a research compound.

An adverse event is any unwanted or unexpected experience that occurs after handling or taking a compound, whether or not it is caused by the compound. The relationship between event and compound is not always clear; a symptom that appears close in time to a dose is not necessarily caused by the dose, and a symptom that appears far in time is not necessarily unrelated.

Common categories that are worth taking seriously include: injection-site reactions that persist or worsen; systemic reactions such as fever, chills, or malaise; gastrointestinal symptoms (nausea, vomiting, diarrhoea) that persist or intensify; cardiovascular symptoms (palpitations, chest discomfort, syncope); neurological symptoms (severe headache, visual change, weakness, altered mental status); allergic-type symptoms (rash, swelling, difficulty breathing); and any symptom the reader cannot explain from their baseline. When any of these appears, seek clinical evaluation.

The above-the-fold warning at the top of this page lists categories of symptom that call for immediate professional or emergency help. That list is not exhaustive, and it is not diagnostic; its function is to lower the threshold for seeking help, not to raise it.

When in doubt, treat a serious symptom as urgent. Emergency responders would rather be called for a false alarm than not called for a real event.

In the United States, Poison Control can be reached at 1-800-222-1222 (available 24 hours, free, confidential). Contact them for suspected overdoses, accidental exposures, wrong-substance ingestion, or any suspected poisoning. For any other life-threatening emergency, dial the local emergency number and follow the operator's instructions.

Outside the United States, contact the poison-control or emergency service applicable to your country. Do not use Healthy Mango contact addresses for medical emergencies; those addresses are staffed for editorial and legal correspondence, not urgent triage.

If you believe a claim on the site is unsupported by its cited source, or that a documented protocol has been transcribed incorrectly, please write to support@healthymango.org with the page URL, the specific claim, and the source you believe conflicts with it. Where we agree, we correct the page. Where we disagree, we explain why.

Peer-reviewed articles and regulatory documents occasionally move, are withdrawn, or change URLs. If you find a citation on the site that no longer resolves, or that resolves to different content than described, please report it to support@healthymango.org with the page URL and the reference identifier. We prefer that broken references be flagged rather than silently tolerated.

Healthy Mango does not sell, dispense, or authenticate research materials. If you suspect that a vial from a specific vendor is counterfeit, mislabelled, contaminated, or otherwise defective, the right first step is to contact that vendor directly and to preserve any packaging, labels, and Certificates of Analysis for evidence.

If the incident involves personal injury or a suspected poisoning, get medical or emergency help first (see the warning at the top of this page) and preserve the material for the treating clinician. You may also send an informational report to support@healthymango.org so that we can consider the vendor and product in future editorial coverage; we do not act as an enforcement authority.

The Reporting card and Contact card below list the appropriate address for each category of correspondence. Use them rather than emailing individual editors. For urgent health emergencies, do not use any Healthy Mango contact address; contact local emergency services or Poison Control as described above.